What You Need to Know
• The Food and Drug Administration approved Rasonque, a new pancreatic cancer drug, on Wednesday.
• Rasonque, developed by Revolution Medicines, is intended for patients with advanced pancreatic cancer who have undergone prior treatment.
• In clinical trials, patients taking Rasonque alongside chemotherapy lived an average of 13.2 months, nearly double the time of those on chemotherapy alone.
The Food and Drug Administration approved Rasonque, also known as daraxonrasib, on Wednesday for patients with advanced pancreatic cancer who have previously received treatment, such as chemotherapy. The drug, developed by Revolution Medicines, showed promising results in a late-stage clinical trial involving 500 patients, where those taking Rasonque along with standard chemotherapy lived an average of 13.2 months, compared to those receiving chemotherapy alone. Dr. Rachna Shroff, chief of the division of hematology and oncology at the University of Arizona Cancer Center, expressed her elation at the trial’s findings, calling it a significant breakthrough in treating pancreatic cancer. While Rasonque has side effects, including a blistering rash and gastrointestinal issues, it targets a mutation in the KRAS gene, which is prevalent in many pancreatic cancers.
Why It Matters
The approval of Rasonque marks a significant advancement in the treatment of pancreatic cancer, which is the third leading cause of cancer death in the United States. With over 67,000 expected diagnoses this year, pancreatic cancer remains one of the most challenging cancers to treat due to a lack of effective screening and early detection methods. The KRAS gene mutation has long been a target for cancer therapies, and Rasonque’s success represents a breakthrough in addressing this mutation, potentially paving the way for future treatments.
Read the Full Story →
